BIOGEN INC. Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax of $500.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-04.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax · last filed 2015-02-04
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2014 was $500.00K, a 6.19% decline from fiscal 2013.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2013 was $533.00K, a 84.14% decline from fiscal 2012.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2012 was $3.36M, a 164.98% increase from fiscal 2011.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2011 was $1.27M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 12 month |
|---|---|
| 2014-12-31 | $500.00K 10-K · filed 2015-02-04 |
| 2013-12-31 | $533.00K 10-K · filed 2015-02-04 |
| 2012-12-31 | $3.36M 10-K · filed 2015-02-04 |
| 2011-12-31 | $1.27M 10-K · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |